Research Article
Depressive and Anxiety Disorders in Systemic Lupus Erythematosus Patients without Major Neuropsychiatric Manifestations
Table 1
General conditions of 176 SLE patients.
| | | Median, IQR |
| | Age (year) | 29.5 (24, 37) | | Disease duration (month) | 8 (1, 32) | | Proteinuria (g/day) | 0.295 (0.1, 1) | | SLEDAI | 11 (6, 17) | | Cumulative dosage | | | Prednisone (g) | 0.93 (0.16, 9) | | CTX (g) | 0 (0, 0.2) | | HCQ (g) | 1 (0, 11.6) | | SLEDAI | 11 (6, 17.75) | | HAMD | 9 (6, 13) | | HAMA | 7 (4, 11) |
| | | (%) |
| | Female | 153 (86.9%) | | Autoantibodies | | | Antinuclear antibody (ANA) | 176 (100.0%) | | Anti-P0 antibody | 68 (38.6%) | | Anti-dsDNA antibody | 92 (52.3%) | | Anti-Sm antibody | 100 (56.8%) | | Anti-U1-RNP antibody | 61 (34.7%) | | Anti-SSA-52 kD antibody | 79 (44.9%) | | Anti-SSA-60 kD antibody | 112 (63.6%) | | Anti-SSB antibody | 47 (26.7%) | | Anti-histones antibody | 96 (54.5%) | | Anti-nucleosome antibody | 86 (48.9%) | | Anticardiolipin (aCL) antibody | 35 (19.9%) | | Lupus anticoagulant complex (LAC) | 60 (34.1%) | | Active disease activity (SLEDAI > 9) | 95 (54.0%) | | Arthritis | 58 (33.0%) | | Myositis | 13 (7.4%) | | Urinary casts | 5 (2.8%) | | Hematuria | 56 (31.8%) | | Proteinuria | 59 (33.5%) | | Pyuria | 65 (36.9%) | | New rash | 57 (32.4%) | | Alopecia | 41 (23.3%) | | Mucosal ulcers | 16 (9.1%) | | Pleurisy | 21 (11.9%) | | Pericarditis | 17 (9.7%) | | Low complement | 143 (81.3%) | | Fever | 38 (21.6%) | | Thrombocytopenia | 30 (17.0%) | | Leukopenia | 49 (27.8%) | | Lupus headache | 6 (3.4%) | | Vasculitis | 10 (5.7%) | | Visual disturbance | 2 (1.1%) | | Seizure, psychosis, organic brain syndrome, cranial nerve disorder, and cerebrovascular accidents | 0 (0%) | | Depression | 14 (8.0%) | | Anxiety | 21 (11.9%) |
|
|
SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; CTX: cyclophosphamide; HCQ: hydroxychloroquine; HAMD: Hamilton Depression Rating Scale; HAMA: Hamilton Anxiety Rating Scale.
|
